Market
Neumora's next major strategic move by end of 2025
2
Resolution / Starting Odds
Partnership with another pharmaceutical company • 25%
Acquisition by another company • 25%
Launch of a new drug development program • 25%
No major strategic move • 25%
Official announcements from Neumora Therapeutics or major news outlets
Story
Neumora's Navacaprant Fails in KOASTAL-1 Phase 3 Trial; Shares Plunge 83%
Jan 2, 2025, 01:40 PM
Neumora Therapeutics (NMRA) shares plummeted by up to 83% after the company announced that its experimental drug navacaprant failed to meet the primary and key secondary endpoints in the Phase 3 KOASTAL-1 study for the treatment of major depressive disorder (MDD). This marks the company's first late-stage readout. The study did not demonstrate a statistically significant improvement in the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6, nor in the key secondary endpoint of the Snaith-Hamilton Pleasure Scale (SHAPS) score. Despite the setback, Neumora is continuing with two other identical Phase 3 trials, KOASTAL-2 and KOASTAL-3. Some analysts expressed skepticism over the company's interpretation of subgroup analyses suggesting efficacy in women but not in men. The failure of navacaprant, which targets the kappa opioid receptor (KOR) antagonist pathway, underscores the challenges in developing new treatments for depression and comes amid tough competition in the KOR antagonist space.
View original story
Similar markets
Launches own venture • 25%
Joins another streaming company • 25%
No major move announced • 25%
Takes executive role in a non-streaming company • 25%
Not disclosed • 25%
Extended beyond mid-2026 • 25%
Remains until mid-2026 • 25%
Reduced to before mid-2026 • 25%
Virtual reality and wearables • 25%
Social media enhancements • 25%
Other • 25%
AI and machine learning • 25%
Partnership or joint venture • 25%
Acquisition of another company • 25%
Merger with another company • 25%
No significant strategic move • 25%
No new partnership • 25%
Partnership outside Asia-Pacific • 25%
Partnership in Asia-Pacific • 25%
Partnership within Japan • 25%
Shares increase by over 50% • 25%
Shares increase by up to 50% • 25%
Shares remain stable • 25%
Shares decrease • 25%
Acquire another company • 25%
No major strategic move • 25%
Expand to new markets • 25%
Launch new product line • 25%
Divestiture • 25%
New Technology Investment • 25%
Other • 25%
Merger or Acquisition • 25%
Focus on sustainability • 25%
Digital transformation • 25%
No significant change • 25%
Expansion into new markets • 25%
Further Acquisitions • 25%
Focus on Domestic Market • 25%
Partnerships with Other Insurers • 25%
Expansion of Existing Operations • 25%
Other strategic move • 25%
Focus on internal development • 25%
Partnership with another biotech • 25%
Another acquisition in oncology • 25%